Press coverage about Zosano Pharma (NASDAQ:ZSAN) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zosano Pharma earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.1541244187668 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Separately, ValuEngine upgraded Zosano Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

Shares of Zosano Pharma (ZSAN) traded up $0.01 during trading hours on Friday, reaching $0.58. The company had a trading volume of 410,718 shares, compared to its average volume of 572,180. Zosano Pharma has a 52 week low of $0.56 and a 52 week high of $3.54.

Zosano Pharma (NASDAQ:ZSAN) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). equities analysts forecast that Zosano Pharma will post -0.9 earnings per share for the current year.

In related news, Director Kenneth Greathouse purchased 95,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were purchased at an average cost of $0.62 per share, with a total value of $58,900.00. Following the transaction, the director now directly owns 95,000 shares in the company, valued at approximately $58,900. The purchase was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders bought 200,000 shares of company stock worth $123,450. Insiders own 2.95% of the company’s stock.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/zosano-pharma-zsan-earning-somewhat-favorable-media-coverage-accern-reports/1756279.html.

Zosano Pharma Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Insider Buying and Selling by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.